AstraZeneca PLC (AZN)vsPsyence Biomedical Ltd. Common Shares (PBM)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
PBM
Psyence Biomedical Ltd. Common Shares
$6.59
+29.72%
HEALTHCARE · Cap: $16.17M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PBM
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for PBM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : PBM
The strongest argument for PBM centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : PBM
The primary concerns for PBM are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
PBM carries more volatility with a beta of 0.31 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 23/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Psyence Biomedical Ltd. Common Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Psyence Biomedical Ltd. (PBM) is a pioneering biotechnology company dedicated to unlocking the therapeutic potential of psychedelic compounds, specifically in the realms of mental health and wellness. By employing a vertically integrated approach, Psyence excels in the cultivation, formulation, and clinical research of psilocybin and other psychedelic substances, with the objective of developing innovative therapies to address pressing mental health issues. Supported by a strong intellectual property portfolio and a promising clinical pipeline, the company is well-positioned to capitalize on the growing acceptance of psychedelics in healthcare, addressing the urgent demand for accessible and effective mental health solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?